DeZwarteRidder schreef op 5 oktober 2014 17:21:
Pharming en Salix moeten wel opschieten, want over 8 en 10 jaar lopen de patenten af en kunnen de Chinezen Ruconest bijna gratis gaan verkopen.
--------------------------------------------------------------------------
Ruconest could position itself as a differentiated product, with a benign safety profile, to provide rapid relief to acute HAE attack symptoms.
Santarus is anticipating that a salesforce of 25 reps should be sufficient to target the allergy/immunology practices where the estimated ~6,000-8,000 U.S. HAE patients likely seek treatment. Recall that Ruconest benefits from Orphan Drug designation in the U.S., and that as a biologic product, it is expected to benefit from 12 years of data
exclusivity upon potential FDA approval.
Ruconest also benefits from broad IP coverage, with two patents expiring in 2022 or 2024.